Zealand’s obesity strategy and Immunovant’s curious development plan
This week on "The Readout LOUD" podcast: Zealand's obesity strategy, Immunovant's curious development plan, and more.
How do obesity biotechs compete against Novo Nordisk and Eli Lilly? Why does gene therapy pioneer Jim Wilson think there’s “irrational pessimism” in the field? And why isn’t Immunovant advancing the drug it just reported positive data on?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about positive data from Immunovant’s autoimmune drug candidate, a patient death linked to Sarepta’s gene therapy, and dispatches from our STAT Breakthrough Summit East in New York.
